Loading...
The use of statins has been associated with decreased incidence and improved outcomes in prostate cancer. Statins are substrates of SLCO2B1, an organ anionic transporter that enables precursors of dihydroxytestosterone (DHT) to enter prostate cancer cells. Genetic variants of this transporter are associated with variability in response to androgen deprivation therapy (ADT). Also, prior studies have shown that statins block uptake of androgen dehydroepiandrosterone sulfate (DHEAS), a precursor of testosterone and a substrate for SLCO2B1, by competitively binding to SLCO2B1.
To determine whether the use of statins prolongs time to prostate cancer progression during ADT, investigators conducted a retrospective study of 926 patients treated for …